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ABSTRACT
Neprilysin (NEP) is a zinc metalloproteinase that degrades enkephalins, endothelins, and
the Alzheimer’s disease amyloid β (Aβ) peptides. NEP-deficient mice possess increased
levels of brain Aβ 1-40 and Aβ 1-42. The objective of this study was to determine whether
tissue NEP specific activity differs according to age and/or across mouse strains,
especially those strains predisposed toward formation of Aβ-amyloid plaques following
overexpression of the human Alzheimer amyloid precursor protein (APP). The C57Bl/6J
mouse strain appears to be relatively susceptible to cerebral amyloidosis, whereas the
Swiss Webster (SW) strain appears more resistant.

We investigated whether NEP

specific activity in brain and kidney homogenates from SW and C57 mice of 6, 40, and
80 weeks old varied according to mouse strain, age, and gender. Among the variables
tested, NEP specific activity varied most dramatically across mouse strain, with the
kidney and brain of SW mice displaying the highest activities. Aging was associated
with a reduction in brain NEP specific activity in both strains.

Gender-specific

differences were identified in kidney but not in brain. We conclude that aging- and
strain-dependent differences in NEP specific activity may play a role in the differential
susceptibility of some mouse strains for developing cerebral amyloidosis following
human APP overexpression.
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INTRODUCTION

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the
accumulation of senile plaques and neurofibrillary tangles in the brain [1]. The senile
plaques are composed of amyloid-β peptides (Aβ; Aβ 1−40 and Aβ 1−42) that are generated
by the sequential enzymatic cleavage of the amyloid precursor protein by β- and γsecretases [for review, see 9]. Aβ deposition is associated with dysfunction and/or death
of neurons in the human central nervous system, leading to deterioration of memory and
higher cognitive function [29]. Research toward developing treatments for AD are
focused on preventing the formation of the Aβ via development of β- and γ-secretase
inhibitors or strategies for directly antagonizing Aβ accumulation, using either “plaquebuster” drugs or immunotherapy to aid in clearing the brain of plaques [reviewed in 9].
Another potential therapeutic target focuses on activation of specific proteases that
metabolize Aβ peptides, thereby clearing them from the brain.

Candidate proteases

included insulin degrading enzyme (IDE) [30, 33] and neprilysin (NEP) [17].

Neprilysin (NEP) is a 97 kDa type II transmembrane zinc-metalloproteinase that is also
known as neutral endopeptidase, enkephalinase, EC 3.4.24.11, CD10, and common acute
lymphoblastic leukemia antigen [6,16]. NEP is expressed in the mammalian CNS and
peripheral tissues, including kidney, lung, and reproductive organs [6 15, 16].
Structurally, NEP is a type II transmembrane protein, displaying a long extracellular
domain that contains the catalytic site, an intramembranous domain, and a short Nterminal intracellular domain. By virtue of this structure, NEP acts as an ectoenzyme,
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catalyzing cleavage in the extracellular space [25]. Recently, NEP has drawn much
attention because of its ability to degrade Aβ40 and Aβ42 in vitro and in vivo [13, 17, 27,
28, 32], cleaving the Aβ 1-42 peptide between the Glu3-Phe4, Gly9-Trp10, Phe19-Phe20,
Ala30-Ile31, Gly33-Leu34 [13] or Gly37-Gly38 [17] peptide bonds.

Injection of NEP

inhibitors into the mouse brain results in an accumulation of Aβ peptides [17, 25], and
transgene-induced overexpression of NEP decreases Aβ levels and plaque load [24].
Additionally, NEP knockout mice show increased levels of both Aβ40 and Aβ42
peptides [26].

In the current study, we sought to test further the hypothesis that alterations in
endogenous NEP specific activity might be modulated by age, gender [3, 18] and/or
strain, and that modulation of NEP specific activity as a function of these variables might
contribute to differential brain Aβ deposition following overexpression of human APP in
transgenic mice.
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MATERIALS AND METHODS
Reagents
Phosphoramidon, enalapril and the fluorogenic substrate N-dansyl-D-Ala-Gly-p-nitroPhe-Gly were purchased from Sigma (St. Louis, MO, USA)[6,7,12]. Recombinant human
neprilysin (rhNEP) [14] was purchased from R&D (Minneapolis, MN, USA).
Phosphoramidon and enalapril were dissolved in water; the substrate peptide was
dissolved in methanol and then brought to 2 mM with Tris (50 mM, pH 7.4).

Preparation of Kidney and Brain Homogenates
Mice derived from the Swiss Webster (SW; 6 wk old mice from Charles River; 40 wk old
mice from Taconic) and C57Bl/6J strains (6 and 40 wk old mice from Jackson Labs)
were sacrificed by cervical dislocation. SW and C57 mice of 52 wks of age were
purchased from Taconic and Jackson Labs, respectively, and aged in our facility. All
mice were maintained with free access to food and water, but without environmental
enrichment [21]. Upon sacrifice, kidneys and brain were immediately removed and
placed into 1 ml of ice-cold 50 mM Tris-HCl, pH 7.4. The tissue was homogenized by
30 strokes in a dounce homogenizer and sonicated (BranSonic sonifier) on ice for 15 sec
(2x).

The homogenates were transferred to a sterile microcentrifuge tube for

centrifugation at 10,000 x g at 4o C for 15 min to remove cell debris and nuclei. These
samples were transferred to another sterile microcentrifuge tube, and the centrifugation
was repeated. Final protein concentrations were determined using the BioRad® protein
assay kit (Hercules, CA, USA), utilizing bovine serum albumin as the standard. The
brain and kidney homogenates were stored at -80º until use.
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NEP activity
Mouse tissue homogenates of brain or kidney and a standard curve of rhNEP (5 ng/ml – 5
µg/ml) were pre-incubated with enalapril, an angiotensin-converting enzyme (ACE)
inhibitor, for 30 minutes at 37ºC to prevent fluorogenic substrate (N-dansyl-D-Ala-Gly-pnitro-Phe-Gly) cleavage by ACE [20], in the presence or absence of phosphoramidon, a
specific NEP inhibitor. Following this pre-incubation, the fluorogenic substrate was
added, and samples were incubated for an additional 1-2 hours at 37ºC.

The final

concentrations were 12.5 µM for enalapril, 12.5 µM for phosphoramidon, and 500 µM
for the substrate, in a reaction volume of 100 µl.

At each indicated time point,

fluorescence absorbance was recorded using a Perkin-Elmer Victor3 Reader (Forster City,
CA, USA) with an emission wavelength of 535 nm and an excitation wavelength of 355
nm. Arbitrary fluorescence units for each sample were compared with a standard curve
prepared using rhNEP in order to determine the NEP specific activity per mg protein.

Statistical Analyses
Analysis of variance (2-way ANOVA) was used to compare NEP specific activity in SW
mice across ages and genders for both brain and kidney samples, and across age and
strain (SW and C57B/6J). For all analyses, the confidence limit was set at p< 0.05.
When a significant difference was determined by the 2-way ANOVA, an analysis of
variance (1-way ANOVA) or Student’s t-test (confidence limits of p< 0.05) was also
performed. All statistical analyses were performed using Prism® 3.0 software. The data
are presented as means ± SEM.
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RESULTS
rh Neprilysin Standardization
The activity of recombinant human neprilsyin (rhNEP) was determined at 4
concentrations (0.005, 0.05, 0.5 and 5 µg/ml; n=3) following incubation for 1, 2 and 4
hours in the absence or presence of phosphoramidon, a specific NEP inhibitor. At the
lowest concentration, 0.005 µg/ml (5 ng/ml), NEP activity was undetectable. As the
concentration of rhNEP was increased, the amount of NEP activity increased in a
concentration-dependent manner, as indicated by an increase in fluorometric emission.
Further, NEP activity displayed a time dependency at the 0.5 µg/µl concentration.
Phosphoramidon blocked the activity of rhNEP at all concentrations and times of
incubation (data not shown).

Neprilysin activity in kidney and brain as a function of age, gender and strain

a) Kidney

NEP activity was assayed in the kidney of young (6 wk), old (40 wk) and aged (80 wk)
male and female SW mice (Fig 1A).

Kidney homogenate from female SW mice

displayed a neprilysin specific activity (sp act) equivalent to 6.35 ± 0.29 ng rhNEP/mg of
kidney protein. In male SW mice, the neprilysin activity was equivalent to 2.51 ± 0.21
ng rhNEP/mg kidney protein. A two-way ANOVA demonstrated that kidney neprilysin
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specific activity varied significantly according to gender (p < 0.0001; Fig 1A) but was not
apparently altered with aging from 6 to 80 wk of age (p = 0.85).

We also sought to determine whether kidney NEP specific activity varied according to
background mouse strain. NEP specific activity was assayed in kidney homogenates of
male mice from the two strains (SW and C57Bl/6J, n = 5) at two ages (6 and 40 weeks)
Kidney NEP specific activity was significantly different between these mouse strains
(ANOVA two-way, p < 0.05). SW displayed higher specific activity (2.68 ± 0.23 ng
rhNEP/mg kidney protein) compared to C57Bl/6J (2.05± 0.13 ng/mg kidney protein)
(ANOVA one-way, p < 0.05; C57Bl/6J vs SW). Neither strain showed an effect of aging
on kidney NEP specific activity (Fig 1B).

b) Brain

In contrast to kidney, brain NEP specific activity in SW mice did not vary according to
gender but rather varied in both genders according to age (ANOVA two-way; age, p =
0.0001; gender, p = 0.53) (Fig 2A). NEP specific activity at 80 weeks was significantly
(~75%) reduced in both males and females relative to 6 weeks (one-way ANOVA, p <
0.0002). NEP specific activity in brain was also significantly different as a function of
background mouse strain (ANOVA two-way, p < 0.001) (Fig 2B). In the male mouse
brain, NEP specific activity was significantly lower in the C57Bl/6J strain when
compared to activity in the SW mouse brain at the ages of both 6 and 40 weeks. By the
age of 80 weeks, however, both strains displayed a significant decrease in NEP specific
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activity, such that activities between the two strains was no longer significantly different.
A two-way ANOVA indicated that both age (p<0.0001) and strain (p<0.01) affected NEP
specific activity. Furthermore, a one-way ANOVA analysis within strains showed that at
the age of 80 weeks, NEP specific activity was significantly different compared to the
activity at ages of 6 or 40 weeks (SW p<0.01; C57 p<0.01 and p<0.05. Fig. 2B).
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DISCUSSION
In humans, the propensity toward cerebral amyloidosis varies according to gender,
genetic background, organ, and aging. In the current study, we sought to test in mice the
hypothesis that endogenous alterations in tissue NEP specific activity might be
modulated by aging, gender or strain, and that modulation of NEP specific activity as a
function of these variables might contribute to differential brain Aβ deposition following
overexpression of human APP in transgenic mice. As reviewed below, it is worth noting
that data already exist that implicate the mouse background strain and aging in
modulating the relative propensity toward Aβ accumulation.

Role of genetic background in specifying the propensity toward cerebral Aβ amyloidosis

Unsurprisingly, the various Aβ plaque-forming mice reported in the literature have been
created in a variety of genetic background strains. Of these, the only line containing the
Swiss-Webster strain background is the PDAPP mouse, which is SW X C57Bl/6J X DBA
and expresses APP at approximately 10-fold relative to endogenous levels [19]. Despite
such exceptional levels of APP holoprotein expression, Aβ deposition occurs in only
50% of the animals despite identical transgene dose. PDAPP mice that fail to develop Aβ
plaques are designated “low pathology” mice [7], a heritable trait that might plausibly be
attributable to the SW and/or DBA components of the background strain. Our lab’s
experience is consistent with this formulation. We created a line of APPSWE SW mice that
demonstrated a 5-fold overexpression of the APP transgene relative to endogenous APP
levels. This level of APP fold-increase is clearly associated with plaque accumulation in
10
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C57Bl/6J mice in other labs [2], yet our APPSWE SW mice demonstrated no plaque
accumulation, even at 24 months of age, and even after back-crossing with C57Bl/6J for
one or two generations (Gandy and Ehrlich, unpublished data).

In recent work, Lamb and colleagues have proposed that the propensity toward
Aβ deposition is at least partially controlled by genetic background [23]. In their studies,
the Lamb group showed that YAC-APP transgenic mice on a congenic C57Bl/6J
background showed Aβ plaque deposition as early as age 13 months, while YAC-APP
transgenic mice on the DBA/2J background failed to produce plaques despite an identical
level of overexpressed mutant APP [23].

Role of gender in specifying the propensity toward cerebral Aβ amyloidosis

Gender-related differences in plaque deposition in transgenic mice are also well
recognized [e.g., 22]. Female APPSWE transgenic mice generated in a mixed strain
background (C57Bl/6 X SJL) demonstrate greater amyloid deposition than do their male
littermates, and this becomes more apparent with age [4, 22, 34]. In the current study,
gender differences were examined only in the SW strain, and we observed that female
kidney NEP specific activity was significantly higher than corresponding male kidney
NEP specific activity; however, NEP specific activity was similar in males and females in
the brains of these same animals.

Follow-up studies of the effect of estrogen and

testosterone on NEP specific activity are underway since other studies along this line
suggest that hormones are important regulators of NEP activity [14].
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Role of aging in specifying the propensity toward cerebral Aβ amyloidosis

In SW mice, and to a lesser extent in C57Bl/6J mice, we found that brain NEP specific
activity is dramatically diminished in the aged brain, implying that this is not a strainspecific occurrence.

These results agree with other studies that reported an aging-

dependent diminution in brain NEP activity [3, 18]. In C57Bl/6 male mice, NEP specific
activity and protein levels are reported to decrease in the hippocampus by 20% over the
lifespan from 10 to 132 weeks, while a much smaller decrease can be demonstrated in the
neocortex [18]. In a mixed C57Bl6/129 background, neprilysin protein levels are reported
to decrease by greater than 50% in the hippocampus between 2 and 18 (78 weeks)
months [3]. Of note, however, the decrease in C57Bl/6J was far greater than that shown
in the study by Iwata et al. [18], implying that there may be differences between substrains of C57Bl, and/or that the differences in the total brain may be greater than in the
hippocampus alone. The latter formulation appears unlikely, however, based on the
correlation between our results and those from LaFerla and colleagues [3].

Cerebral Aβ clearance and the role of neprilysin

The literature supports the hypothesis that there might plausibly be direct links between
levels of NEP activity and that of Aβ pathology. For example, injection of a lentivirus
expressing the NEP gene decreased AD pathology in plaque-forming PDAPP and
TASD41 transgenic mice [25, 26].

The inhibitors of NEP, thiorphan and
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phosphoramidon, were shown to block the proteolyzing activity of brain derived NEP on
3

H/14C Aβ 1-42 peptide [12]. When transgenic mice overexpressing NEP are crossed with

plaque forming mice, brain Aβ levels and plaque deposition both decrease [24].

Despite recent advances in defining the role of NEP in cerebral Aβ clearance, the
molecular and cellular mechanisms underlying clearance of brain Aβ are incompletely
understood. Both Aβ 1-40 and Aβ 1-42 are cleared rapidly from the blood and localized to
the liver, spleen, kidney, urine, and stomach [11] with the liver accounting for 60% of Aβ
concentration [12]. Therefore, reductions in NEP specific activity in the periphery may
also play a role in the accumulation of soluble Aβ in AD brains by shifting the
concentration gradient away from the circulation and toward brain absorption and
subsequent plaque deposition.

The “peripheral sink” phenomenon associated with Aβ

immunotherapy [7] dovetails well with such a concept, and the apparent success of that
strategy in mouse models supports the notion that concomitant augmentation of both
peripheral and central Aβ clearance may be an attractive approach to treatment or
prevention of cerebral amyloidosis in AD.

Conclusions
In summary, we have investigated the role of background mouse strain, gender, and aging
on the specific activity of NEP in two tissues. Among the variables tested, NEP specific
activity varied most dramatically across mouse strain, with the highest activities being
observed in the kidney and brain of SW mice. Aging was associated with a reduction in
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brain NEP specific activity in both strains. We conclude that aging- and strain-dependent
differences in NEP specific activity may explain, at least in part, the roles that aging and
background mouse strain play in differential specification of the susceptibility toward the
development of cerebral Aβ amyloidosis.
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FIGURE LEGENDS
Fig 1.: Kidney NEP as a function of gender, aging, and mouse strain.
A) Neprilysin specific activity is higher in female than in male, but independent from age
(ANOVA two-way, p=0.85 for age, p<0.0001 for gender). Samples evaluated for gender
only (Student’s t-test * p<0.0001). The data are expressed as mean ± SEM ng/mg kidney
protein. B) Neprilysin activity in males of 2 different strains: Swiss Webster and C57/6J
(ANOVA two-way, p=0.39 for age, p<0.05 for strain). Samples from A evaluated for
strain only (Student’s t-test * p<0.05). The rhNEP specific activity is expressed as mean
± SEM ng/mg kidney protein.

Fig 2.: Brain NEP in SW mice as a function of gender, aging and mouse strain.
A) Neprilysin activity does not differ in Swiss Webster female or male but decreases with
age (ANOVA two-way, p<0.0001 for age, p=0.53 for gender). Samples evaluated for age
only (ANOVA One-way * p<0.01, ** p<0.001). The rhNEP specific activity is expressed
as mean ± SEM pg/mg brain protein. B) Neprilysin activity in males of 2 different
strains: Swiss Webster and C57/6J (ANOVA two-way, p<0.0001 for age, p<0.01 for
strain). Samples evaluated for one strain only (ANOVA One-way: p<0.001 for SW,
p<0.01 for C57. Bonferroni analysis: * p<0.01, ** p<0.05). The rhNEP specific activity
is expressed as mean ± SEM pg/mg brain protein.
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